Table 1

Baseline data

TrialTreatmentNFemale (%)RF positive (%)AgeDuration of RASDAIHAQTSS
BELIRAGlucocorticoids7789.668.853.8±12.110±825.9±13.71.14±0.7138.1±45.4
ASPIREInfliximab45270.171.149.5±12.80.8±0.737.9±12.41.5±0.6711.1±15.1
MTX17574.074.249.2±12.90.8±0.738.0±11.51.53±0.5912.0±17.0
PREMIERAdalimumab13974.181.952.7±13.30.7±0.748.1±13.61.59±0.5918.9±19.1
Adalimumab+MTX17472.880.151.6±14.50.7±0.848.4±15.01.47±0.6319.0±21.5
MTX14373.175.952.6±13.20.8±0.949.4±14.11.5±0.6623.0±24.0
ERAEtanercept13972.974.750.7±13.31.0±1.044.8±15.51.46±0.6610.7±14.0
MTX14567.878.248.6±12.91.1±0.943.8±15.91.44±0.5911.5±12.4
TEMPOEtanercept15176.668.853.0±13.96.3±5.136.1±14.21.39±0.6826.4±48.4
Etanercept+MTX16973.766.252.4±12.56.8±5.434.2±15.61.38±0.6933.0±45.3
MTX13678.465.352.8±12.86.8±5.541.5±16.71.49±0.7433.9±48.5
ATTRACTInfliximab19076.778.252.9±11.610.2±8.146.6±14.81.64±0.6166.9±62.2
Placebo4280.977.651.4±12.110.5±8.443.8±13.61.60±0.6370.1±68.1
DE019Adalimumab+MTX32273.884.255.7±12.210.7±9.440.6±12.61.45±0.6266.0±53.4
LEFLeflunomide29472.772.657.9±10.24.0±4.249.6±13.61.5±0.6927.8±35.6
MTX27272.372.657.1±11.03.8±3.650.6±13.21.49±0.6724.2±34.8
Salazopyrine3565.274.658.4±11.16.1±8.647.7±12.51.33±0.6444.3±55.8
  • ASPIRE, ‘Active-controlled Study of Patents receiving Infliximab for the treatment of RA of Early onset’; ATTRACT, ‘Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy’; BELIRA, ‘BEst LIfe with Rheumatoid Arthritis’; ERA, ‘Early Rheumatoid Arthritis’; HAQ, Health Assessment Questionnaire; LEF, leflunomide; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TEMPO, ‘Trial of Etanercept and Methotrexate with radiographic Patient Outcomes’; TSS, total Sharp score.